The NAI classification issued by the US FDA is the most sought after and corresponds to the highest level of compliance. At 2.57 pm, Sun Pharma ... impacts of an import alert for its Halol ...
SBI Multi Asset Allocation Fund - Direct (IDCW-Q) 15.48 100000 0.39 SBI Multi Asset Allocation Fund - Direct (IDCW-M) 15.48 100000 0.39 SBI Multi Asset Allocation ...
Sun Pharma Q3 results today: What to expect from India’s top ... The company’s Halol plant, receiving an import alert from the USFDA earlier in December, remains a challenge for Sun. The earnings ...
Import Alert 99-48, Detention without Physical Examination of Foods Due to Chemical Contamination, includes a broad range of synthetic contaminants, including benzene, dioxins, polychlorinated ...
The U.S. branch of India’s Sun Pharma issued a voluntary recall of more ... The Class II recall, which is what the FDA defines as situations that may cause temporary health consequences or ...
Hellen de Kloet, Business Head – Western Europe, Australia, and New Zealand, Sun Pharma, said, “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines ...
Sun Pharmaceutical ... and Sun Pharma to improve the lives of patients affected by skin conditions," Cosmo President of the Dermatology Division Diana Harbort said. Advisory Alert: It has come ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...
Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country’s largest pharmaceutical (pharma) company ...
Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country’s largest pharmaceutical (pharma) company ...
As stated by Hellen de Kloet, business head – Western Europe, Australia and New Zealand, Sun Pharma “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in ...